Post by Boehringer Ingelheim

#NEWS: Full data from two of our Phase III trials in people living with #obesity and overweight were presented today at #ADA2026. Obesity is a chronic, complex disease driven by underlying metabolic dysfunction and is closely connected to serious conditions such as liver disease, type 2 diabetes and cardiovascular disease.     By deepening our understanding of these interconnected conditions, these data highlight opportunities for more integrated approaches to reduce long‑term risk and support overall metabolic health. The results were simultaneously published in the New England Journal of Medicine and Nature Medicine. Read more 👉 https://lnkd.in/eRxv2PpB #LifeForward #ADASciSessions